Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib

Circulating endothelial cells are a potential biomarker for patients with renal cell carcinoma (RCC) with and without von Hippel Lindau (VHL) syndrome

(2017) R. S. Bhatt et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor

(2017) T. E. Hutson et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study

(2017) B. G. Redman et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib

(2009) Laura Vroling et al.   ANGIOGENESIS

Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival

(2008) H. van Cruijsen et al.   CLINICAL CANCER RESEARCH

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY